Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bioptix, Inc.
J&J Pumps MedTech Growth; Offers $16.6BN+ For Abiomed
Johnson & Johnson plans to buy Abiomed for $380 per share – about $16.6bn in total – plus up to $35 per share in potential commercial and clinical milestone-contingent payments. Abiomed is the clear leader in percutaneous circulatory support technology, but would benefit from J&J's reach and resources while complementing J&J's Biosense Webster electrophysiology business.
Integra Adds ACell’s Regenerative Tech As It Dumps Extremity Orthopedics
Integra will pay up to $400m for ACell to expand its wound management and soft-tissue repair product line. The deal is part of a larger restructuring plan that includes selling its orthopedics business.
Tech Transfer Roundup: Tonix Inks Trio Of COVID-19-Focused Deals
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
MTI Top 100: Leading Medtechs See Steady Organic Growth In A Market On The Cusp Of Change
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
- In Vitro Diagnostics
- Other Names / Subsidiaries
- AspenBio Pharma
- BiOptix Diagnostics, Inc.
- Venaxis, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.